

Target Name	Adenosine A ₃ receptor
Target TTD ID	TTDS00189

Target Species	Human
Chemical Type	Thiazole derivatives
Mode of Action	Antagonist
Activity Type	Adenosine A ₃ binding affinity
QSAR Model 1	$pK_i = -3.951(\pm 2.415)q_2 - 2.623(\pm 2.136)q_5 + 2.441(\pm 1.489)q_7 - 0.275(\pm 0.261)\log P$ $- 1.498(\pm 0.763)I_{\text{OBu}_t} + 0.895(\pm 0.614)I_{\text{Me}_t} + 4.030$ $n = 30, \quad R_a^2 = 0.744, \quad R^2 = 0.797, \quad R = 0.893, \quad F = 15.0(\text{df}6, 23), \quad s = 0.483,$ $Q^2 = 0.689, \quad \text{SDEP} = 0.523, \quad S_{\text{PRESS}} = 0.597, \quad \text{PRESS} = 8.2, \quad \text{bsr}^2(\pm \text{sd}) = 0.798(\pm 0.007)$
QSAR Model 2	$pK_i = 0.280(\pm 0.118)f_2 + 0.415(\pm 0.118)f_3 - 0.368(\pm 0.118)f_4 - 0.239(\pm 0.118)f_6$ $- 0.424(\pm 0.118)f_7 + 0.459(\pm 0.118)f_8 + 4.401$ $n = 30, \quad R_a^2 = 0.895, \quad R^2 = 0.916, \quad R = 0.957, \quad F = 42.0(\text{df}6, 23), \quad s = 0.310,$ $Q^2 = 0.870, \quad \text{SDEP} = 0.338, \quad S_{\text{PRESS}} = 0.386, \quad \text{PRESS} = 3.4, \quad \text{bsr}^2(\pm \text{sd}) = 0.917(\pm 0.001)$
QSAR Model 3	$pK_i = -1.940(\pm 2.072)q_2 - 11.413(\pm 3.878)q_8 - 13.611(\pm 5.005)q_9 - 0.038(\pm 0.029)[\log P]^2$ $- 1.556(\pm 0.722)I_{\text{OBu}_t} + 3.083$ $n = 30, \quad R_a^2 = 0.775, \quad R^2 = 0.814, \quad R = 0.902, \quad F = 21.0(\text{df}5, 24), \quad s = 0.452,$ $Q^2 = 0.753, \quad \text{SDEP} = 0.466, \quad S_{\text{PRESS}} = 0.521, \quad \text{PRESS} = 6.5, \quad \text{bsr}^2(\pm \text{sd}) = 0.814(\pm 0.007)$

QSAR Model 4	$pK_i = -1.932(\pm 2.150)q_2 - 11.413(\pm 4.012)q_8 - 13.741(\pm 5.189)q_9 - 0.311(\pm 0.260)\log P$ $- 1.518(\pm 0.747)I_{\text{OBu}_t} + 3.686$ <p> $n = 30, R_a^2 = 0.762, R^2 = 0.803, R = 0.896, F = 19.6(\text{df}5, 24), s = 0.465,$ $Q^2 = 0.739, \text{SDEP} = 0.479, S_{\text{PRESS}} = 0.536, \text{PRESS} = 6.9, \text{bsr}^2(\pm \text{sd}) = 0.804(\pm 0.007)$ </p>
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: MoDel and e-dragon</p> <p>q_x: Wang-Ford charge of atom x (x may take values 1 to 14).</p> <p>I_{OBu_t}: Indicator variable having value 1 if tert-butyloxy group is present at R position, 0 otherwise.</p> <p>I_X: Indicator variable having value 1 if X =N, value 0 otherwise.</p> <p>I_{Me_t}: Indicator variable having value 1 if R = methyl or ethyl, value 0 otherwise.</p>
Reference	<p>Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A₃ receptor antagonists using FA and GFA techniques. <i>Bioorganic & Medicinal Chemistry</i> 13 (2005) 1159–1165</p>

Target Species	Human
Chemical Type	Thiadiazole derivatives
Mode of Action	Antagonist
Activity Type	Adenosine A ₃ binding affinity
QSAR Model 1	$pK_i = -3.951(\pm 2.415)q_2 - 2.623(\pm 2.136)q_5 + 2.441(\pm 1.489)q_7 - 0.275(\pm 0.261)\log P$ $- 1.498(\pm 0.763)I_{\text{OBu}_t} + 0.895(\pm 0.614)I_{\text{Me}_t} + 4.030$ <p> $n = 30, R_a^2 = 0.744, R^2 = 0.797, R = 0.893, F = 15.0(\text{df}6, 23), s = 0.483,$ $Q^2 = 0.689, \text{SDEP} = 0.523, S_{\text{PRESS}} = 0.597, \text{PRESS} = 8.2, \text{bsr}^2(\pm \text{sd}) = 0.798(\pm 0.007)$ </p>

<p>QSAR Model 2</p>	$pK_i = 0.280(\pm 0.118)f_2 + 0.415(\pm 0.118)f_3 - 0.368(\pm 0.118)f_4 - 0.239(\pm 0.118)f_6 - 0.424(\pm 0.118)f_7 + 0.459(\pm 0.118)f_8 + 4.401$ <p>$n = 30, R_a^2 = 0.895, R^2 = 0.916, R = 0.957, F = 42.0(\text{df}6, 23), s = 0.310, Q^2 = 0.870, \text{SDEP} = 0.338, S_{\text{PRESS}} = 0.386, \text{PRESS} = 3.4, \text{bsr}^2(\pm \text{sd}) = 0.917(\pm 0.001)$</p>
<p>QSAR Model 3</p>	$pK_i = -1.940(\pm 2.072)q_2 - 11.413(\pm 3.878)q_8 - 13.611(\pm 5.005)q_9 - 0.038(\pm 0.029)[\log P]^2 - 1.556(\pm 0.722)I_{\text{OBu}_t} + 3.083$ <p>$n = 30, R_a^2 = 0.775, R^2 = 0.814, R = 0.902, F = 21.0(\text{df}5, 24), s = 0.452, Q^2 = 0.753, \text{SDEP} = 0.466, S_{\text{PRESS}} = 0.521, \text{PRESS} = 6.5, \text{bsr}^2(\pm \text{sd}) = 0.814(\pm 0.007)$</p>
<p>QSAR Model 4</p>	$pK_i = -1.932(\pm 2.150)q_2 - 11.413(\pm 4.012)q_8 - 13.741(\pm 5.189)q_9 - 0.311(\pm 0.260) \log P - 1.518(\pm 0.747)I_{\text{OBu}_t} + 3.686$ <p>$n = 30, R_a^2 = 0.762, R^2 = 0.803, R = 0.896, F = 19.6(\text{df}5, 24), s = 0.465, Q^2 = 0.739, \text{SDEP} = 0.479, S_{\text{PRESS}} = 0.536, \text{PRESS} = 6.9, \text{bsr}^2(\pm \text{sd}) = 0.804(\pm 0.007)$</p>
<p>Molecular Descriptor</p>	<p>Access the following web-servers to compute molecular descriptors: MoDel and e-dragon</p> <p>q_x: Wang-Ford charge of atom x (x may take values 1 to 14).</p> <p>I_{OBu_t}: Indicator variable having value 1 if tert-butyloxy group is present at R position, 0 otherwise.</p> <p>I_X: Indicator variable having value 1 if X =N, value 0 otherwise.</p> <p>$I_{\text{Me}_t\text{Et}}$: Indicator variable having value 1 if R = methyl or ethyl, value 0 otherwise.</p>
<p>Reference</p>	<p>Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques. <i>Bioorganic & Medicinal Chemistry</i> 13 (2005) 1159–1165</p>

<p>Target Species</p>	<p>Human</p>
<p>Chemical Type</p>	<p>1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives</p>

Mode of Action	Antagonist
QSAR Model 1	$pK_i = 1.913\sigma_p + 0.684I_{NO_2} + 4.654$ $n = 17, R_a^2 = 0.726, R^2 = 0.760, R = 0.872, F = 22.2(df\ 2, 14), s = 0.465,$ $Q^2 = 0.653, SDEP = 0.507, S_{PRESS} = 0.559, PRESS = 4.4$
QSAR Model 2	$pK_i = 0.320f3 + 0.518f4 + 0.332f5 + 0.396f6 - 0.187f7 + 4.294$ $n = 17, R_a^2 = 0.786, R^2 = 0.853, R = 0.923, F = 12.7(df\ 5, 11), s = 0.411,$ $Q^2 = 0.631, SDEP = 0.524, S_{PRESS} = 0.651, PRESS = 4.6$
QSAR Model 3	$pK_i = 1.847\sigma_p + 0.792I_{NO_2} - 2.375q_{15} + 2.507q_{19} + 4.452$ $n = 17, R_a^2 = 0.744, R^2 = 0.808, R = 0.899,$ $Q^2 = 0.648, LSE = 0.143, SDEP = 0.511, S_{PRESS} = 0.608, PRESS = 4.4$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: MoDel and e-dragon</p> <p>q_x: Wang–Ford charge of atom x (x may take values 1–20)</p> <p>I_{NO_2}: Indicator variable having value 1 if nitro group is present at the R1 position, value 0 otherwise</p> <p>I_{NH_2}: Indicator variable having value 1 if amino group is present at the R1 position, value 0 otherwise</p> <p>I'_{NH_2}: Indicator variable having value 1 if amino group present at position 8, value 0 otherwise</p>
Reference	QSAR of adenosine A3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools. Bioorganic & Medicinal Chemistry Letters 15 (2005) 3737–3743

Target Species	Rat
Chemical Type	Adenosine analogues
Mode of Action	Agonist
Activity	Displacement of specified [^{125}I] AB-MECA binding at rat A ₃ receptors expressed in CHO cells

Type	
QSAR Model 1	$\log(K_i) = 11.619 + 4.204 \cdot BELm7 + 11.721 \cdot BELv2 -$ $7.415 \cdot BEHe7 + 5.610 \cdot BEHp3 + 13.131 \cdot BELp5 - 7.010 \cdot BELp6$ <p>N = 32 R = 0.899 S = 0.322 F_{exp} = 17.535 p < 10⁻⁵ q²_{LOO} = 0.724 S_{cv-LOO} = 0.385</p>
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: MoDel and e-dragon</p> <p>Constitutional: nCIC, RBF, nDB, nS, nR05, nR06</p> <p>Topological: X4A, X5A, Lop, IC3, IC5, T(N..S)</p> <p>Molecular walk count: MWC05, MWC08, MWC10, SRW05, SRW07, SRW10</p> <p>BCUT: BEHm8, BELm1, BELm2, BEHe7, BEHp5, BEHp7</p> <p>Galvez topological charge indices: GGI4, GGI6, GGI7, JGI1, JGI8, JGI9</p> <p>2D autocorrelations: MATS3m, MATS1e, MATS2e, MATS1p, GATS8v, GATS8v</p> <p>Randic ´molecular profiles: DP04, DP06, SP01, SP02, SP03, SHP2</p> <p>Geometrical: J3D, MAXDN, MAXDP, MEcc, G(N..N), G(O..I)</p> <p>RDF: RDF130u, RDF140v, RDF050v, RDF050p, RDF140p, RDF155p</p> <p>3D-MORSE: Mor16m, Mor18m, Mor20m, Mor08e, Mor12e, Mor10p</p> <p>WHIM: E1v, L2e, G3m, L2p, E1s, Gm</p> <p>GETAWAY: R3u+, R1m+, R3v+, R3e+, R5e+, R7e+</p>
Reference	<p>Quantitative Structure Activity Relationships as Useful Tools for the Design of New Adenosine Receptor Ligands. 1. Agonist. <i>Current Medicinal Chemistry</i>, 2006, 13, 2253-2266</p>